Protecting the aged heart during cardiac surgery: Use of del Nido cardioplegia provides superior functional recovery in isolated hearts

Arun Govindapillai, BSc,a Rui Hua, PhD,b Robert Rose, PhD,a Camille Hancock Friesen, MD, b,c,d and Stacy B. O’Blenes, MDa,b,c

Objectives: Aged hearts are particularly vulnerable to ischemia-reperfusion injury. Our objective was to determine if del Nido cardioplegia, which contains lidocaine, less blood, and less calcium than our standard cardioplegia, provides superior protection for aged hearts. We also sought to determine if the lidocaine in del Nido cardioplegia is adequate to prevent Na+ influx via the window current.

Methods: Sodium channel kinetics were measured in rat cardiomyocytes with and without lidocaine. Recovery after 60 minutes of cardioplegic arrest was assessed in isolated working senescent rat hearts. Del Nido cardioplegia was delivered as a single dose (n = 8) because it is used clinically, and standard cardioplegia was delivered as an induction dose with re-dosing every 20 minutes (n = 8). After 20 minutes of reperfusion, hearts were switched to working mode for 60 minutes. Flows were indexed to ventricular dry weight. Troponin release was assayed.

Results: Sodium channel kinetics indicated that the lidocaine concentration in del Nido cardioplegia minimizes the potential for Na+ influx via the window current. Spontaneous contractions occurred in fewer hearts arrested with del Nido cardioplegia (88% vs 13%; P = .01), and troponin release was reduced (0.24 vs 0.89 ng/mL; P = .017). Cardiac output was approximately 90% of baseline in the del Nido group compared with approximately 50% in the standard group (173 ± 14 vs 86 ± 22 mL · min⁻¹ · g⁻¹; P = .0008). Stroke work was higher in the del Nido group (93 ± 6 vs 41 ± 10 mL · mm Hg · g⁻¹; P = .0002).

Conclusions: Del Nido cardioplegia prevents spontaneous contractions during arrest, reduces troponin release, and results in superior myocardial function in isolated aged hearts. Del Nido cardioplegia has the potential to provide superior myocardial protection for older patients undergoing cardiac surgery. (J Thorac Cardiovasc Surg 2013;146:940-948)

The growing number of elderly patients requiring cardiac surgery is an important group at higher risk for cardiac dysfunction and death postoperatively. 1,2 Aged hearts are particularly susceptible to reperfusion injury after the ischemic periods that occur during cardiac surgery 3-5 owing to changes in the way cardiomyocytes deal with intracellular Ca²⁺, particularly during ischemia. 5-8

Del Nido cardioplegia is used in several centers for myocardial protection during pediatric cardiac surgery. 9-11 Compared with the standard 4:1 blood cardioplegia we use in our adult practice, del Nido cardioplegia is more dilute (1:4 blood:crystalloid), has approximately 75% less Ca²⁺, and contains lidocaine (Table 1). Del Nido cardioplegia usually is given as a single dose, 9-11 whereas our standard cardioplegia is given as an induction dose followed by maintenance doses approximately every 20 minutes. The del Nido cardioplegia strategy results in lower postoperative troponin release in pediatric patients compared with our standard cardioplegia. 9

Because elderly myocardium is similar to immature myocardium in that both are particularly susceptible to reperfusion injury related to Ca²⁺ overload, 3-8,12-14 we hypothesized that a del Nido cardioplegia strategy may also be beneficial in the elderly. We previously showed, in cardiomyocytes from aged rats (≈ 24 mo), that arrest with del Nido cardioplegia results in less activity during the ischemic period, lower diastolic Ca²⁺ during ischemia and reperfusion, and avoidance of Ca²⁺-induced hypercontraction during early reperfusion. 15 The objective of this study was to determine if the beneficial effects seen with del Nido cardioplegia in aged cardiomyocytes translate into improved functional recovery in elderly whole hearts.

Sodium influx is thought to be the main cause of intracellular Ca²⁺ accumulation during ischemia by driving reverse-mode Na⁺/Ca²⁺ exchange. 16,17 During hyperkalemic cardioplegic arrest, membrane depolarization opens a proportion of the voltage-gated Na⁺ channels...
spanning the cell membrane. Most of these channels are inactivated rapidly, thereby preventing action potential generation and propagation, but a small fraction remain tonically available and allow Na\(^+\) to flow into the cell via a window current.\(^{18-20}\) Lidocaine used as an additive to depolarizing cardioplegia may limit Na\(^+\) influx by blocking the window current, however, this has not been well described. We investigated whether the concentration of lidocaine present in del Nido cardioplegia is adequate to minimize the potential for Na\(^+\) influx via the window current.

**MATERIALS AND METHODS**

**Experimental Animals and Anesthesia**

Experiments were performed in accordance with guidelines published by the Canadian Council on Animal Care.\(^{21}\) Male Fisher 344 rats (3-4 mo for isolated cardiomyocyte studies, and 23-24 mo for isolated heart studies) obtained from Charles River Laboratories (Saint-Constant, Canada) were heparinized (intraperitoneally, 3000 U/kg; Pharmaceutical Partners of Canada, Richmond, Ontario, Canada), and anesthetized with sodium pentobarbital (intraperitoneally, 160 mg/kg; Veterinary Medication Distribution Centre; Saint-Hyacinthe, Quebec, Canada). Hearts were removed rapidly and placed in ice-cold Tyrode’s solution for isolated cardiomyocyte studies (NaCl 140 mmol/L, KCl 5.4 mmol/L, Na\(_2\)HPO\(_4\) 1 mmol/L, CaCl\(_2\) 1 mmol/L, MgCl\(_2\) 1 mmol/L, glucose 10 mmol/L, HEPES 5 mmol/L, pH 7.4), or Krebs-Henseleit buffer for isolated heart studies (NaCl 118 mmol/L, KCl 4.7 mmol/L, NaHCO\(_3\) 25.0 mmol/L, KH\(_2\)PO\(_4\) 1.20 mmol/L, CaCl\(_2\) 2.50 mmol/L, MgSO\(_4\) 1.20 mmol/L, glucose 11 mmol/L, ethylenediaminetetraacetic acid 0.5 mmol/L, equilibrated with 95% O\(_2\)/5% CO\(_2\), pH 7.4).

**Cardiomyocyte Isolation**

Ventricular cardiomyocytes were obtained by enzymatic dissociation. Hearts cannulated via the aorta were perfused with Tyrode’s solution (37°C, 5 min), followed by 10 minutes with Ca\(^{2+}\)-free Tyrode’s, then Tyrode’s containing collagenase type II (73.7 U/mL; Worthington Biochemical Corp, Lakewood, NJ), taurine (20 mmol/L), CaCl\(_2\) (30 \(\mu\)M), and bovine serum albumin (0.1%). The right ventricle was dissected off and manually triturated to separate individual cardiomyocytes, which were stored in Kraf-Brühe solution (K-glutamate 100 mmol/L, K-aspartate 10 mmol/L, KCl 2.5 mmol/L, KH\(_2\)PO\(_4\) 10 mmol/L, MgSO\(_4\) 2 mmol/L, glucose 20 mmol/L, taurine 20 mmol/L, creatine 5 mmol/L, ethylene glycol tetraacetic acid 0.5 mmol/L, HEPES 5 mmol/L, bovine serum albumin 0.1%, pH 7.2). Only quiescent rod-shaped myocytes with clear striations were selected for these studies.

**Electrophysiological Solutions and Protocols**

The sodium current (I\(_{Na}\)) was recorded in single cardiomyocytes using the whole-cell patch-clamp technique with reduced extracellular Na\(^+\) concentrations to facilitate voltage clamping. Myocytes were superfused with modified Tyrode’s (NaCl 12 mmol/L, CsCl 130 mmol/L, TEA-Cl 5.4 mmol/L, CaCl\(_2\) 1 mmol/L, MgCl\(_2\) 1 mmol/L, HEPES 10 mmol/L, glucose 5 mmol/L, pH 7.4, 22°C-23°C) including NiCl\(_2\) (40 \(\mu\)M) and nitrendipine (10 \(\mu\)M) to block Ca\(^{2+}\) currents. The pipette solution contained CsCl 135 mmol/L, CaCl\(_2\) 0.1 mmol/L, MgCl\(_2\) 1 mmol/L, NaCl 5 mmol/L, ethylene glycol tetraacetic acid 10 mmol/L, Mg-adenosine triphosphate 4 mmol/L, Na-phosphocreatine 6.6 mmol/L, Na-guanosine triphosphate 0.3 mmol/L, and HEPES 10 mmol/L, pH 7.2. The resistance of the borosilicate glass micropipettes (1.5 mm outer diameter, 0.75 mm inner diameter) was 3 to 5 MΩ; seal resistance was 2 to 15 GΩ, and rupturing the sarcolemma in the patch for voltage clamp experiments resulted in access resistances of 5 to 15 MΩ. Series resistance compensation averaged 80% to 85% using an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, Calif). Data were digitized using a Digidata 1440 and pCLAMP 10 software (Molecular Devices).

The voltage clamp protocol for measuring I\(_{Na}\) current-voltage relationships and activation kinetics consisted of holding myocytes at -100 mV and then giving a series of 20-ms, 10-mV steps from -80 to +60 mV. I\(_{Na}\) activation kinetics were determined by calculating chord conductance (G) using the following equation: G = I/(V\(_{m}\) - E\(_{Na}\)). Only quiescent rod-shaped myocytes were included in this study, and held at -100 mV and then exposed to ambient room temperature (22°C-23°C) for a 60-minute ischemic period. Reperfusion then was collected and frozen (−80°C) for later determination of troponin concentration (2010-3-HS, rat serum cardiac troponin-I enzyme-linked immunosorbsent assay; Life Diagnostics, Inc). After a total of 15 minutes, hearts were switched to constant pressure mode for an additional 5 minutes and then into working heart mode for 5 minutes (preload, 20 cm H\(_2\)O; afterload, 100 cm H\(_2\)O). Only hearts that met the following predetermined baseline criteria were used in this study: heart rate greater than 200 bpm, regular rhythm, cardiac output greater than 25 mL/min, and coronary flow greater than 10 mL/min.\(^{22}\) After the baseline working heart period, hearts were arrested with cardioplegia as described later, and then exposed to ambient room temperature (22°C-23°C) for 60 minutes. Reperfusion then was collected and frozen (−80°C) for later determination of troponin concentration (2010-3-HS, rat serum cardiac troponin-I enzyme-linked immunosorbsent assay; Life Diagnostics, Inc). After exposure to ambient room temperature (22°C-23°C) for 60 minutes, hearts were switched to constant pressure mode for an additional 5 minutes and then into working heart mode for 60 minutes. At the end of the protocol, the ventricles were blotted dry, weighed, then desiccated at 80°C for 24 hours and re-weighed. All flow values were indexed to dry weight of the ventricles.

**Cardioplegia Preparation and Delivery**

Autologous blood was collected from the chest cavity using a syringe containing heparin (200 U) as the hearts were being harvested. Cardioplegia solutions were prepared according to our clinical protocols (Table 1), cooled in an ice bath, and oxygenated. Before delivery, the cardioplegia was filtered using a 20-μm pore size vacuum filter (EMD Millipore, Billerica, Md). The cardioplegia temperature was 1.9°C ± 0.4°C.

The cardioplegia strategies used in this study were modeled after those we use in the clinic.\(^{23}\) Standard cardioplegia was delivered as an induction dose (15 mL/kg) followed by additional doses (5 mL/kg) every 20 minutes.
The Journal of Thoracic and Cardiovascular Surgery • October 2013

942

Statistical Analysis

Data are presented as mean ± SEM. Tests for statistical significance included the following: paired t test, unpaired t test, the Fisher exact test, and mixed linear model analysis followed by the Tukey-Kramer test where appropriate.

RESULTS

The Lidocaine Concentration Used in del Nido Cardioplegia Minimizes the Potential for Na⁺ Window Current During Cardiopulic Arrest

To determine if the lidocaine concentration in del NIDO cardioplegia is adequate to minimize the potential for Na⁺ influx via the window current, Na⁺ channel activation and inactivation curves were examined in the presence and absence of lidocaine 0.36 mmol/L (Figure 1). Lidocaine shifted the inactivation curve to the left (V_{1/2}\text{[act]} = 101.2 ± 0.7 vs −88.9 ± 0.3 mV; P = .00019; n = 8), with no change in slope factor, indicating lower Na⁺ channel availability at any given membrane potential. Furthermore, the activation curve was shifted to the right (V_{1/2}\text{[act]} = −47.7 ± 0.7 vs −56.7 ± 0.4 mV; P < .001; n = 8), indicating that opening of available channels is reduced with lidocaine at any given membrane potential. The result of this shift in the activation and inactivation curves away from each other is that the Na⁺ window current, represented by the area under the 2 curves, is minimized with lidocaine 0.36 mmol/L (Figure 1, B).

Del Nido Cardioplegia Reduces the Incidence of Spontaneous Activity During Cardiopulic Arrest, and Delays Return of Activity During Reperfusion

To determine the relative ability of del NIDO cardioplegia to protect aged hearts, we studied senescent rats using our working heart model of arrest with blood cardioplegia. Sixteen of 20 hearts (80%) met the predetermined functional criteria for inclusion in the study. Eight hearts were arrested with standard cardioplegia and 8 were arrested with del NIDO cardioplegia. Cardiac temperature was 21°C ± 1°C in each group after induction and essentially was unchanged immediately before reperfusion (20°C ± 1°C in each group).

Spontaneous electromechanical activity was observed during the arrest period in 7 of 8 hearts in the standard cardioplegia group (Figure 2). This was in the form of occasional wide complex beats seen on the electrocardiogram (Figure 2, A) with accompanying mechanical activity. In contrast, spontaneous activity was seen in only 1 of 8 hearts arrested with del NIDO cardioplegia (Figure 2, B; P = .01).

After the start of reperfusion, all hearts had spontaneous return of rhythm. However, the time to return of the first heartbeat was twice as long in the del NIDO group when compared with the standard cardioplegia group (Figure 2, C and D; 67 ± 6 vs 32 ± 5 s; P = .0007). All hearts had occasional extra systoles or short runs of bigeminy during the reperfusion period. Four hearts in the standard cardioplegia group and 1 heart in the del NIDO group (P = not specified [NS]) had short runs of sustained tachyarrhythmia that resolved spontaneously. One heart in the del NIDO group had a short period of asystole, which was not seen in any of the hearts protected with standard cardioplegia.

Use of del Nido Cardioplegia Results in Less Myocardial Damage and Lower Coronary Vascular Resistance During Reperfusion

To assess the impact of del NIDO cardioplegia on cardiomyocyte damage after arrest and reperfusion, we assayed troponin I in the coronary effluent. Troponin levels were approximately 70% less in hearts protected with del NIDO cardioplegia when compared with standard cardioplegia (0.24 ± 0.05 vs 0.89 ± 0.23 ng/mL; P = .02). We examined coronary vascular resistance during the retrograde perfusion phase of reperfusion and found that
it was approximately 50% less in hearts arrested with del Nido cardioplegia (0.75 ± 0.05 vs 1.43 ± 0.31 mm Hg · min · mL⁻¹ · g⁻¹; P = .0497). This was caused by an increase in resistance over baseline in the standard cardioplegia group, which was not seen in the del Nido cardioplegia group (Δ coronary vascular resistance 0.68 ± 0.22 vs −0.05 ± 0.04 mm Hg · min · mL⁻¹ · g⁻¹; P = .007).

Del Nido Cardioplegia Is Associated With Superior Functional Recovery After Cardioplegic Arrest

To evaluate the impact of del Nido cardioplegia on functional recovery, the hearts were switched into working mode for 60 minutes after the 20-minute reperfusion period, and hemodynamic parameters were examined at fixed filling pressure (20 cm H₂O, Table 2, Figure 3). All hearts

---

**FIGURE 1.** Analysis of lidocaine impact on Na⁺ channel activation and inactivation kinetics. A, Activation (dashed line) and inactivation (solid line) curves were generated in the presence and absence (control) of lidocaine 0.36 mmol/L as found in del Nido cardioplegia. Lidocaine shifts the activation curve to the right and the inactivation curve to the left. B, Magnified view of the area highlighted in panel A. The area under the intersection of the control activation and inactivation curves (solid arrow) represents the Na⁺ window current. This is minimized in the presence of lidocaine (open arrow).

**FIGURE 2.** Analysis of spontaneous activity during cardioplegic arrest and return of first heart beat after reperfusion. A, Representative tracings of spontaneous ECG activity (upper panel), and Ao pressure fluctuation (lower panel) in a heart arrested with standard cardioplegia. B, Bar graph representing the percentage of hearts showing spontaneous activity during arrest with either standard or del Nido cardioplegia. C, Representative ECG tracings from the start of reperfusion in hearts arrested with standard (upper panel) and del Nido cardioplegia (lower panel). D, Bar graph representing the average time to return of the first heart beat after reperfusion in hearts arrested with standard and del Nido cardioplegia. Bars represent the mean ± SEM (n = 8 hearts per group). Ao, Aortic; ECG, electrocardiogram.
completed the entire protocol with the exception of 1 in each group in which air was entrained near the end of the studies and therefore did not contribute data for the final 2 time points. Hemodynamic parameters were not significantly different during baseline working heart mode in hearts arrested with either standard or del Nido cardioplegia (Table 2, Figure 3). After reperfusion, hearts protected with del Nido cardioplegia had higher peak systolic pressure, left ventricular developed pressure, and rate pressure product (Table 2, Figure 3). Cardiac output was higher throughout the working heart period in hearts arrested with del Nido cardioplegia as was stroke volume and stroke work (Table 2, Figure 3).

### DISCUSSION

Aged myocardium behaves differently than mature myocardium during ischemia and is not as well protected by some cardioplegia solutions. \(^{23,24}\) This may be one reason why older patients undergoing cardiac surgery have impaired recovery of ventricular function and lower survival when compared with younger adult patients. \(^{1,2}\)

The mechanism responsible for the intolerance to ischemia appears to be related to accelerated accumulation of intracellular Ca\(^{2+}\). \(^{5-8}\) Strategies to limit the accumulation of intracellular Ca\(^{2+}\) in aged hearts improve the recovery of ventricular function after ischemia. \(^{7,8}\) In previous studies, \(^{15}\) we observed that del Nido cardioplegia, developed for the protection of immature myocardium, potentially has beneficial effects in cardiomyocytes from aged rats. The results of our current study comparing a del Nido cardioplegia strategy with a standard multidose 4:1 blood cardioplegia strategy suggest that those benefits translate into reduced myocardial damage and improved functional recovery in the whole aged heart. The rats used for these isolated heart studies were 23 to 24 months of age. Survival to this age in this strain of rats is approximately 50%, \(^{25}\) which corresponds to a human age of older than 70 years (World Health Organization mortality statistics, 2013).

### TABLE 2. Hemodynamic parameters measured during working heart mode

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Baseline</th>
<th>5</th>
<th>10</th>
<th>15</th>
<th>30</th>
<th>45</th>
<th>60</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart rate (bpm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Standard</td>
<td>224 ± 6</td>
<td>197 ± 16</td>
<td>200 ± 16</td>
<td>200 ± 16</td>
<td>204 ± 19</td>
<td>198 ± 21</td>
<td>198 ± 22</td>
</tr>
<tr>
<td>del Nido</td>
<td>219 ± 6</td>
<td>228 ± 8</td>
<td>231 ± 9</td>
<td>235 ± 6</td>
<td>233 ± 9</td>
<td>233 ± 11</td>
<td>229 ± 12</td>
</tr>
<tr>
<td>P</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Systolic pressure (mm Hg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Standard</td>
<td>133 ± 5</td>
<td>99 ± 6</td>
<td>99 ± 6</td>
<td>99 ± 7</td>
<td>93 ± 9</td>
<td>98 ± 9</td>
<td>97 ± 8</td>
</tr>
<tr>
<td>del Nido</td>
<td>138 ± 4</td>
<td>128 ± 4</td>
<td>127 ± 5</td>
<td>128 ± 4</td>
<td>127 ± 4</td>
<td>125 ± 5</td>
<td>123 ± 4</td>
</tr>
<tr>
<td>P</td>
<td>.5</td>
<td>.0006</td>
<td>.0008</td>
<td>.0006</td>
<td>.0001</td>
<td>.0011</td>
<td>.0018</td>
</tr>
<tr>
<td>Rate pressure product (×10^2 mm Hg · min⁻¹)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Standard</td>
<td>30 ± 1</td>
<td>20 ± 2</td>
<td>20 ± 2</td>
<td>20 ± 2</td>
<td>19 ± 3</td>
<td>20 ± 3</td>
<td>20 ± 3</td>
</tr>
<tr>
<td>del Nido</td>
<td>30 ± 1</td>
<td>29 ± 1</td>
<td>29 ± 1</td>
<td>30 ± 1</td>
<td>29 ± 1</td>
<td>29 ± 1</td>
<td>28 ± 1</td>
</tr>
<tr>
<td>P</td>
<td>.8</td>
<td>.0005</td>
<td>.0006</td>
<td>.0002</td>
<td>.0002</td>
<td>.0006</td>
<td>.0017</td>
</tr>
<tr>
<td>Cardiac output (mL · min⁻¹ · g⁻¹)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Standard</td>
<td>181 ± 18</td>
<td>85 ± 23</td>
<td>87 ± 23</td>
<td>88 ± 24</td>
<td>86 ± 24</td>
<td>92 ± 23</td>
<td>86 ± 22</td>
</tr>
<tr>
<td>del Nido</td>
<td>196 ± 9</td>
<td>177 ± 14</td>
<td>180 ± 16</td>
<td>181 ± 15</td>
<td>177 ± 14</td>
<td>174 ± 13</td>
<td>173 ± 14</td>
</tr>
<tr>
<td>P</td>
<td>.6</td>
<td>.0007</td>
<td>.0006</td>
<td>.0007</td>
<td>.0009</td>
<td>.0017</td>
<td>.0008</td>
</tr>
<tr>
<td>Stroke volume (×10⁻² mL · g⁻¹)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Standard</td>
<td>81 ± 7</td>
<td>40 ± 10</td>
<td>41 ± 10</td>
<td>41 ± 10</td>
<td>40 ± 10</td>
<td>43 ± 10</td>
<td>40 ± 10</td>
</tr>
<tr>
<td>del Nido</td>
<td>90 ± 4</td>
<td>78 ± 6</td>
<td>78 ± 6</td>
<td>77 ± 5</td>
<td>76 ± 5</td>
<td>75 ± 5</td>
<td>76 ± 4</td>
</tr>
<tr>
<td>P</td>
<td>.4</td>
<td>.0009</td>
<td>.0009</td>
<td>.0013</td>
<td>.0016</td>
<td>.0026</td>
<td>.0008</td>
</tr>
<tr>
<td>Coronary flow (mL · min⁻¹ · g⁻¹)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Standard</td>
<td>97 ± 5</td>
<td>61 ± 9</td>
<td>60 ± 9</td>
<td>61 ± 7</td>
<td>60 ± 11</td>
<td>65 ± 11</td>
<td>61 ± 12</td>
</tr>
<tr>
<td>del Nido</td>
<td>103 ± 7</td>
<td>101 ± 6</td>
<td>101 ± 6</td>
<td>101 ± 6</td>
<td>101 ± 6</td>
<td>99 ± 6</td>
<td>101 ± 9</td>
</tr>
<tr>
<td>P</td>
<td>.6</td>
<td>.0009</td>
<td>.0008</td>
<td>.001</td>
<td>.0007</td>
<td>.0014</td>
<td>.0003</td>
</tr>
</tbody>
</table>

Mixed linear model analysis was not significant so post hoc comparisons were not performed (n = 8 per group up to the 30-minute time point, and n = 7 for the 45- and 60-minute time points). NS, Not significant.
Lidocaine, which is found in del Nido cardioplegia, is a common additive but the mechanism of benefit is not clearly understood. Possibilities include coronary vasodilation to improve cardioplegia delivery, prevention of reperfusion arrhythmias, and reduction of Na\(^+\) influx via the window current during arrest. During cardioplegic arrest, membrane potential stabilizes at a relatively depolarized level at which a small tonic inward Na\(^+\) current is active. This window current is related to a small proportion of the voltage gated Na\(^+\) channels that are available, open, and in the active state. This is one potential drawback of depolarizing cardioplegic arrest because Na\(^+\) influx is thought to be the prime driver of Ca\(^{2+}\) overload. With a view to potential optimization of the del Nido cardioplegia formulation, we confirmed that lidocaine shifts the activation and inactivation curves for Na\(^+\) channels in a way that minimizes the potential for Na\(^+\) window current. This may represent an important mechanism of benefit with del Nido cardioplegia, and the lidocaine concentration in the current formulation appears sufficient.

Analogous to the observations in our previous isolated cardiomyocyte study, we found a reduction in spontaneous activity in hearts arrested with del Nido cardioplegia. This may be related to Na\(^+\) channel blockade with lidocaine, but del Nido cardioplegia also contains slightly more potassium and magnesium than our standard cardioplegia, resulting in more pronounced membrane depolarization that also may contribute to more effective arrest. Reduced spontaneous activity during the ischemic period should limit the development of intracellular acidosis, which drives the Na\(^+\), and subsequently Ca\(^{2+}\), influx that contributes to ischemia-reperfusion injury.

The time to the return of the first heartbeat was twice as long with del Nido cardioplegia. This corresponds with what we observed anecdotally in our clinical practice when we switched from standard to del Nido cardioplegia for our pediatric patients. This may represent a residual effect of lidocaine but it is not clear if the delayed resumption of rhythm plays any role in the benefit seen with del Nido cardioplegia. It is possible that a period of persistent inactivity during early reperfusion may improve myocardial recovery in a manner similar to that seen with the use of warm terminal cardioplegia.

During ischemia and reperfusion, the late or persistent inward Na\(^+\) current is increased, which can predispose to early after potentials and arrhythmia.
late Na⁺ current can be reduced by Na⁺ channel blockers including lidocaine. In our study we saw no episodes of ventricular fibrillation and only a few runs of tachycardia that were short and self-limiting. We did not see a significant reduction with del Nido cardioplegia, but we cannot exclude the possibility that this might become apparent in a larger study.

Coronary resistance during reperfusion was increased in the standard cardioplegia group but not in the del Nido cardioplegia group. This also may be related to the presence of lidocaine in del Nido cardioplegia, which can promote coronary arteriolar vasodilation. However, there are alternative explanations including the possibility of increased microvascular obstruction related to hypothermia-induced sludging, with the higher hematocrit level in the 4:1 standard cardioplegia.

In the adult, blood cardioplegia appears to offer superior myocardial protection when compared with crystalloid cardioplegia. However, the optimal dilution of the cardioplegia solution is the subject of ongoing debate. Although the benefits of blood cardioplegia are apparent with minimal hematocrit level, it has been suggested that concentrated blood cardioplegia improves recovery by limiting the development of myocardial edema. We did not see any difference in myocardial edema in this study comparing del Nido (1:4 blood:crystalloid) and standard cardioplegia (4:1). This may be because, despite different dilutions, the estimated final oncotic pressure is similar in both solutions (Table 1). Potential advantages of dilute cardioplegia include reduced viscosity that may enhance cardioplegia delivery, and reduced potential for sludging and microvascular obstruction with hypothermia. Furthermore, all the Ca²⁺ in these cardioplegia solutions comes from the blood component, so del Nido cardioplegia has a lower Ca²⁺ concentration, which may be beneficial, particularly in elderly hearts in which strategies to limit Ca²⁺ influx can reduce ischemia-reperfusion injury.

This study was a comparison of 2 cardioplegia strategies that currently are used clinically, therefore del Nido cardioplegia was administered as a single dose and standard cardioplegia was delivered in multiple doses. Evidence suggests that, in adults, multidose 4:1 blood cardioplegia offers benefits over a single dose (reviewed by Buckberg), and is the strategy we currently use clinically. In contrast, del Nido cardioplegia, which typically is used as a single dose, or is re-dosed at long intervals, compares favorably with multidose 4:1 cardioplegia. However, this is primarily in pediatric patients in whom there is some evidence that re-dosing of cardioplegia is detrimental. Therefore, the efficacy of single-dose del Nido cardioplegia in children could be related in part to the patient population rather than the cardioplegia solution itself. Although some centers are using del Nido cardioplegia in adults with single dosing or long intervals between doses (60-120 min), it remains to be determined if multiple dosing with del Nido cardioplegia could provide additional benefits in mature or aged hearts, and what the optimal re-administration volume or interval would be. It should be kept in mind that the administration of large volumes of del Nido cardioplegia could result in increased systemic lidocaine levels that may be a safety issue, particularly in patients with impaired renal function.

**Limitations**

The isolated heart model used in this study had several limitations that must be considered when interpreting our results. The isolated working heart preparation is viable for only a limited time. Although it is possible to examine cardiac function in the short term with this system, it is not feasible to study hearts at more clinically relevant time points (12 or 24 hours after reperfusion). The hearts in this study were exposed to ambient room temperature during the ischemic period, which would limit re-warming compared with the clinical situation in which systemic temperature is usually higher. Furthermore, the isolated heart is not subject to noncoronary collateral flow during the ischemic period, which might alter the efficacy of the myocardial protection strategy by washing out the cardioplegia and/or rewarming the myocardium. The volume of autologous blood that we can collect from each rat is limited. With 4:1 cardioplegia we are able to prepare the induction dose plus 2 additional doses, which allows a maximum 60-minute ischemic period if re-dosing occurs every 20 minutes. If longer ischemic periods were possible, benefits with del Nido cardioplegia might become less apparent if the single-dose strategy becomes inadequate with prolonged cross-clamp times. Although ischemia-reperfusion injury is initiated primarily by Ca²⁺ overload, other processes affect the development of myocardial injury and evolution of functional recovery. For example, the inflammatory system plays a role in the myocardial damage that occurs early after reperfusion. Most of these limitations need to be addressed in future studies in intact animals.

**CONCLUSIONS**

We have shown that in isolated elderly hearts, a del Nido cardioplegia strategy is associated with less spontaneous activity during arrest, reduced myocardial injury, and improved functional recovery when compared with a standard multidose 4:1 blood cardioplegia strategy. Additional studies in a whole animal will help to determine if these results persist in a more clinically relevant model, and justify clinical studies in elderly patients undergoing cardiac surgery.

The authors wish to thank Richard Livingston for his technical support and Karen Buth for statistical support.
References


Discussion

Dr J. William Gaynor (Philadelphia, Pa). I would like to congratulate the authors on a very nice study and an excellent presentation. It is always nice to discuss a paper that agrees with your own beliefs.

We switched to del Nido at the Children’s Hospital in Philadelphia several years ago, and we currently use it for all of our patients from neonates to the young adults. We do not have elderly patients very frequently at CHOP, but we do go into the 30- and 40-year-olds.

Our clinical experience mimics this completely. We usually use a single dose. We see very little return of spontaneous activity, and we have been very happy with the postoperative function.

That being said, when we retrospectively compared our early outcomes, inotropic use, and everything to our previous crystalloid cardioplegia, we could show no differences. So our anecdotal experience is that we like it, it seems to facilitate the operation by only having to give one dose, we do see less spontaneous activity, but we cannot show a clinical difference.

Now, when you go to, as you mentioned in your future directions, you move to elderly patients, you are going to be dealing with myocardium that is ischemic or perhaps has been
subjected to long-term pressure volume overload or in a redo situation. So how do we move forward from this isolated heart model of essentially elderly but normal myocardium to a clinical trial where we can actually show a difference? Because I am afraid it would take so many patients as to become not feasible to perform that study. But that being said, we use del Nido, we are very happy with it, and we do think it is a better myocardial protective strategy.

Thank you very much. I enjoyed your paper.

Mr Govindapillai. Thank you, Dr Gaynor. To try and answer your question, I think that what needs to happen is we need to look at a whole animal model first. There are some concerns in terms of single dosing with del Nido with adult patients where procedures can be pretty long and so sometimes re-dosing can occur over longer intervals than with our standard cardioplegia where it is given in shorter intervals. But I think certainly the next step would be to look at a whole animal model and see where the inflammatory system plays a role as well and that would be, to me, the next logical step before you can move on to some sort of a clinical trial, and hopefully we can see some differences there as well.

Dr Gaynor. We occasionally use multidose if we have a particularly long cross-clamp or in the rare case where we do see a return of activity, and it works very well if you give an additional dose. But again, I think I agree with the findings, I think it is an excellent protective strategy, I think it probably is applicable to a wider range of patients, but I do think it is going to be very hard to prove that in a clinical setting.

Thank you very much.

Mr Govindapillai. Thank you.